Second of two planned phase III trials of eprotirome for the treatment of heterozygous familial hypercholesterolaemia

Trial Profile

Second of two planned phase III trials of eprotirome for the treatment of heterozygous familial hypercholesterolaemia

Discontinued
Phase of Trial: Phase III

Latest Information Update: 14 Feb 2012

At a glance

  • Drugs Eprotirome (Primary)
  • Indications Hyperlipoproteinaemia type IIa
  • Focus Registrational; Therapeutic Use
  • Sponsors Karo Bio
  • Most Recent Events

    • 14 Feb 2012 Status changed from planning to discontinued, according to a Karo Bio media release.
    • 07 Oct 2011 Not official study title
    • 27 Aug 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top